nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B1—Cyclosporine—focal segmental glomerulosclerosis	0.21	0.301	CbGbCtD
Dabrafenib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.166	0.239	CbGbCtD
Dabrafenib—SLC22A6—Cyclosporine—focal segmental glomerulosclerosis	0.135	0.194	CbGbCtD
Dabrafenib—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0887	0.128	CbGbCtD
Dabrafenib—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.06	0.0863	CbGbCtD
Dabrafenib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.036	0.0517	CbGbCtD
Dabrafenib—SLC22A8—nephron—focal segmental glomerulosclerosis	0.0104	0.186	CbGeAlD
Dabrafenib—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.00674	0.0687	CcSEcCtD
Dabrafenib—SIK1—nephron tubule—focal segmental glomerulosclerosis	0.00486	0.0866	CbGeAlD
Dabrafenib—SIK1—kidney—focal segmental glomerulosclerosis	0.00427	0.0761	CbGeAlD
Dabrafenib—SIK1—cortex of kidney—focal segmental glomerulosclerosis	0.00416	0.0741	CbGeAlD
Dabrafenib—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00404	0.0412	CcSEcCtD
Dabrafenib—RAF1—nephron tubule—focal segmental glomerulosclerosis	0.00387	0.0689	CbGeAlD
Dabrafenib—SLC22A6—nephron tubule—focal segmental glomerulosclerosis	0.00375	0.0669	CbGeAlD
Dabrafenib—Azotaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00361	0.0368	CcSEcCtD
Dabrafenib—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.0364	CcSEcCtD
Dabrafenib—RAF1—kidney—focal segmental glomerulosclerosis	0.0034	0.0606	CbGeAlD
Dabrafenib—Gingival bleeding—Cyclosporine—focal segmental glomerulosclerosis	0.00339	0.0346	CcSEcCtD
Dabrafenib—RAF1—cortex of kidney—focal segmental glomerulosclerosis	0.00331	0.059	CbGeAlD
Dabrafenib—SLC22A6—cortex of kidney—focal segmental glomerulosclerosis	0.00321	0.0573	CbGeAlD
Dabrafenib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00317	0.0323	CcSEcCtD
Dabrafenib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00306	0.0312	CcSEcCtD
Dabrafenib—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00303	0.0309	CcSEcCtD
Dabrafenib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00288	0.0294	CcSEcCtD
Dabrafenib—SLCO1B1—kidney—focal segmental glomerulosclerosis	0.00254	0.0453	CbGeAlD
Dabrafenib—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.00236	0.024	CcSEcCtD
Dabrafenib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.023	CcSEcCtD
Dabrafenib—SLC22A8—nephron tubule—focal segmental glomerulosclerosis	0.00225	0.0401	CbGeAlD
Dabrafenib—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.0216	CcSEcCtD
Dabrafenib—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.0216	CcSEcCtD
Dabrafenib—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.0206	CcSEcCtD
Dabrafenib—SLC22A8—kidney—focal segmental glomerulosclerosis	0.00198	0.0352	CbGeAlD
Dabrafenib—SLC22A8—cortex of kidney—focal segmental glomerulosclerosis	0.00192	0.0343	CbGeAlD
Dabrafenib—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00189	0.0193	CcSEcCtD
Dabrafenib—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.0191	CcSEcCtD
Dabrafenib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00174	0.0177	CcSEcCtD
Dabrafenib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.0016	0.0285	CbGeAlD
Dabrafenib—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.0149	CcSEcCtD
Dabrafenib—CYP2C8—kidney—focal segmental glomerulosclerosis	0.00145	0.0258	CbGeAlD
Dabrafenib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.0133	CcSEcCtD
Dabrafenib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0131	CcSEcCtD
Dabrafenib—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.013	CcSEcCtD
Dabrafenib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.0121	CcSEcCtD
Dabrafenib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.0118	CcSEcCtD
Dabrafenib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.0111	CcSEcCtD
Dabrafenib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.011	CcSEcCtD
Dabrafenib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.011	CcSEcCtD
Dabrafenib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.0108	CcSEcCtD
Dabrafenib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.0107	CcSEcCtD
Dabrafenib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.0107	CcSEcCtD
Dabrafenib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.0105	CcSEcCtD
Dabrafenib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.0104	CcSEcCtD
Dabrafenib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000979	0.0175	CbGeAlD
Dabrafenib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000972	0.00991	CcSEcCtD
Dabrafenib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000967	0.00986	CcSEcCtD
Dabrafenib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000955	0.00973	CcSEcCtD
Dabrafenib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00095	0.00969	CcSEcCtD
Dabrafenib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000948	0.00966	CcSEcCtD
Dabrafenib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000877	0.00894	CcSEcCtD
Dabrafenib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000872	0.00888	CcSEcCtD
Dabrafenib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000868	0.00884	CcSEcCtD
Dabrafenib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000864	0.0088	CcSEcCtD
Dabrafenib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000855	0.00871	CcSEcCtD
Dabrafenib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000847	0.00863	CcSEcCtD
Dabrafenib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000842	0.00858	CcSEcCtD
Dabrafenib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000809	0.00825	CcSEcCtD
Dabrafenib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000793	0.00809	CcSEcCtD
Dabrafenib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000789	0.0141	CbGeAlD
Dabrafenib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000778	0.00793	CcSEcCtD
Dabrafenib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000754	0.00768	CcSEcCtD
Dabrafenib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000735	0.00749	CcSEcCtD
Dabrafenib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000727	0.00741	CcSEcCtD
Dabrafenib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000717	0.0073	CcSEcCtD
Dabrafenib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000717	0.0073	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000712	0.00725	CcSEcCtD
Dabrafenib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000701	0.00714	CcSEcCtD
Dabrafenib—ABCB1—kidney—focal segmental glomerulosclerosis	0.000693	0.0124	CbGeAlD
Dabrafenib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000687	0.007	CcSEcCtD
Dabrafenib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000683	0.00696	CcSEcCtD
Dabrafenib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000675	0.012	CbGeAlD
Dabrafenib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000674	0.00687	CcSEcCtD
Dabrafenib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000673	0.00686	CcSEcCtD
Dabrafenib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000667	0.0068	CcSEcCtD
Dabrafenib—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000664	0.00677	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000626	0.00638	CcSEcCtD
Dabrafenib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000621	0.00633	CcSEcCtD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—CD79A—focal segmental glomerulosclerosis	0.000621	0.00413	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—TRPC6—focal segmental glomerulosclerosis	0.000602	0.004	CbGpPWpGaD
Dabrafenib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000597	0.00609	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000593	0.00605	CcSEcCtD
Dabrafenib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000592	0.00604	CcSEcCtD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.000589	0.00392	CbGpPWpGaD
Dabrafenib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000588	0.00599	CcSEcCtD
Dabrafenib—LIMK1—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000584	0.00389	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—COL4A4—focal segmental glomerulosclerosis	0.000578	0.00385	CbGpPWpGaD
Dabrafenib—RAF1—BCR signaling pathway—CD79A—focal segmental glomerulosclerosis	0.000577	0.00384	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000573	0.00382	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000562	0.00573	CcSEcCtD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—MMP9—focal segmental glomerulosclerosis	0.000561	0.00374	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—COL4A4—focal segmental glomerulosclerosis	0.000559	0.00372	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000557	0.00371	CbGpPWpGaD
Dabrafenib—LIMK1—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000557	0.00371	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000556	0.0037	CbGpPWpGaD
Dabrafenib—RAF1—Stimuli-sensing channels—TRPC6—focal segmental glomerulosclerosis	0.000555	0.0037	CbGpPWpGaD
Dabrafenib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000543	0.00554	CcSEcCtD
Dabrafenib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000543	0.00554	CcSEcCtD
Dabrafenib—RAF1—Signaling by PDGF—COL4A1—focal segmental glomerulosclerosis	0.000531	0.00354	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—COL4A1—focal segmental glomerulosclerosis	0.000513	0.00342	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—MMP9—focal segmental glomerulosclerosis	0.000513	0.00341	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000506	0.00516	CcSEcCtD
Dabrafenib—RAF1—Endothelins—EDN1—focal segmental glomerulosclerosis	0.0005	0.00333	CbGpPWpGaD
Dabrafenib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000493	0.00502	CcSEcCtD
Dabrafenib—RAF1—Axon guidance—MYH10—focal segmental glomerulosclerosis	0.000493	0.00328	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.000492	0.00327	CbGpPWpGaD
Dabrafenib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000486	0.00495	CcSEcCtD
Dabrafenib—RAF1—Corticotropin-releasing hormone—GNAQ—focal segmental glomerulosclerosis	0.000476	0.00317	CbGpPWpGaD
Dabrafenib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00047	0.00479	CcSEcCtD
Dabrafenib—SLCO1B1—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	0.00047	0.00312	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-2-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000456	0.00303	CbGpPWpGaD
Dabrafenib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000454	0.00463	CcSEcCtD
Dabrafenib—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.00045	0.00299	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—COL4A3—focal segmental glomerulosclerosis	0.000449	0.00299	CbGpPWpGaD
Dabrafenib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000437	0.00445	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	0.000433	0.00288	CbGpPWpGaD
Dabrafenib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000433	0.00441	CcSEcCtD
Dabrafenib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000433	0.00441	CcSEcCtD
Dabrafenib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00043	0.00439	CcSEcCtD
Dabrafenib—LIMK1—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000429	0.00286	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—CD79A—focal segmental glomerulosclerosis	0.000429	0.00286	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.00042	0.0028	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—PIAS1—focal segmental glomerulosclerosis	0.00041	0.00273	CbGpPWpGaD
Dabrafenib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000408	0.00416	CcSEcCtD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	0.000397	0.00264	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000387	0.00257	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	0.000368	0.00245	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000367	0.00244	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—NOS2—focal segmental glomerulosclerosis	0.000365	0.00243	CbGpPWpGaD
Dabrafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—focal segmental glomerulosclerosis	0.000365	0.00243	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—COL4A4—focal segmental glomerulosclerosis	0.000365	0.00243	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—TRPC6—focal segmental glomerulosclerosis	0.000362	0.00241	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.000352	0.00234	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—PCNA—focal segmental glomerulosclerosis	0.000348	0.00232	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—MMP9—focal segmental glomerulosclerosis	0.000338	0.00225	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—COL4A1—focal segmental glomerulosclerosis	0.000335	0.00223	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.00033	0.00219	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000319	0.00212	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—MMP2—focal segmental glomerulosclerosis	0.000313	0.00208	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000311	0.00207	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	0.000307	0.00204	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	0.000306	0.00204	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.000304	0.00202	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	0.0003	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000289	0.00192	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MYH9—focal segmental glomerulosclerosis	0.000287	0.00191	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—COL4A3—focal segmental glomerulosclerosis	0.000283	0.00188	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.000283	0.00188	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000278	0.00185	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—SPP1—focal segmental glomerulosclerosis	0.000275	0.00183	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.00027	0.0018	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MYH9—focal segmental glomerulosclerosis	0.00027	0.0018	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-11 Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000269	0.00179	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000268	0.00178	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000262	0.00175	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.00026	0.00173	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	0.000255	0.0017	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—MMP2—focal segmental glomerulosclerosis	0.000254	0.00169	CbGpPWpGaD
Dabrafenib—RAF1—IL-3 Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000246	0.00164	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000242	0.00161	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.000239	0.00159	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000237	0.00158	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.000236	0.00157	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—MMP9—focal segmental glomerulosclerosis	0.000236	0.00157	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—AGTR1—focal segmental glomerulosclerosis	0.000232	0.00154	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—FN1—focal segmental glomerulosclerosis	0.000229	0.00153	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000227	0.00151	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.000225	0.00149	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.000221	0.00147	CbGpPWpGaD
Dabrafenib—BRAF—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	0.000215	0.00143	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—FN1—focal segmental glomerulosclerosis	0.000212	0.00141	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	0.000212	0.00141	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	0.000212	0.00141	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—TRPC6—focal segmental glomerulosclerosis	0.000208	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000203	0.00135	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000202	0.00134	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—SPP1—focal segmental glomerulosclerosis	0.000197	0.00131	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000195	0.00129	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	0.000194	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000193	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000193	0.00128	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000192	0.00128	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—MMP9—focal segmental glomerulosclerosis	0.000191	0.00127	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—SPP1—focal segmental glomerulosclerosis	0.00019	0.00126	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.000187	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000186	0.00124	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	0.000181	0.0012	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000177	0.00118	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD79A—focal segmental glomerulosclerosis	0.000174	0.00116	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000173	0.00115	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000172	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.00017	0.00113	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000169	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	0.00016	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—FN1—focal segmental glomerulosclerosis	0.000159	0.00106	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000156	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000155	0.00103	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000151	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	0.000149	0.00099	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000149	0.000988	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.000146	0.00097	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000145	0.000965	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000144	0.000956	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40LG—focal segmental glomerulosclerosis	0.000142	0.000942	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.000141	0.000935	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	0.000136	0.000905	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	0.000134	0.000891	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000134	0.00089	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000133	0.000884	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000131	0.000869	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000129	0.000857	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	0.000128	0.000854	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000127	0.000846	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000126	0.000839	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000125	0.000832	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000122	0.00081	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000119	0.000791	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000117	0.000778	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.000117	0.000778	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.000117	0.000777	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000115	0.000765	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000113	0.000754	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	0.000112	0.000746	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000111	0.000742	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.00011	0.000732	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000106	0.000706	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.0001	0.000666	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MYH9—focal segmental glomerulosclerosis	9.91e-05	0.000659	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	9.9e-05	0.000659	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	9.71e-05	0.000646	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	9.65e-05	0.000642	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—LPL—focal segmental glomerulosclerosis	9.34e-05	0.000622	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	9.19e-05	0.000612	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP2—focal segmental glomerulosclerosis	8.78e-05	0.000584	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	8.76e-05	0.000583	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	8.65e-05	0.000576	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—LIPC—focal segmental glomerulosclerosis	8.54e-05	0.000568	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	8.36e-05	0.000556	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	8.31e-05	0.000553	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	8.3e-05	0.000552	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	8.07e-05	0.000537	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	7.95e-05	0.000529	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	7.93e-05	0.000527	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	7.86e-05	0.000523	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	7.68e-05	0.000511	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CTGF—focal segmental glomerulosclerosis	7.52e-05	0.0005	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.4e-05	0.000492	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	7.38e-05	0.000491	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	7.3e-05	0.000486	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—FN1—focal segmental glomerulosclerosis	7.24e-05	0.000482	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS2—focal segmental glomerulosclerosis	7.16e-05	0.000476	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	7.14e-05	0.000475	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	7.1e-05	0.000472	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	6.99e-05	0.000465	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.92e-05	0.000461	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	6.72e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	6.72e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—focal segmental glomerulosclerosis	6.6e-05	0.000439	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.52e-05	0.000433	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	6.46e-05	0.00043	CbGpPWpGaD
Dabrafenib—BRAF—Disease—LPL—focal segmental glomerulosclerosis	6.41e-05	0.000427	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	6.39e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	6.26e-05	0.000417	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	6.03e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—focal segmental glomerulosclerosis	6.02e-05	0.0004	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD79A—focal segmental glomerulosclerosis	6.01e-05	0.0004	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	5.97e-05	0.000397	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	5.95e-05	0.000396	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—LIPC—focal segmental glomerulosclerosis	5.74e-05	0.000382	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.46e-05	0.000363	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	5.42e-05	0.000361	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	5.39e-05	0.000359	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	5.31e-05	0.000353	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—LPL—focal segmental glomerulosclerosis	5.21e-05	0.000347	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	5.21e-05	0.000346	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	5.16e-05	0.000343	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CTGF—focal segmental glomerulosclerosis	5.05e-05	0.000336	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—focal segmental glomerulosclerosis	5.01e-05	0.000333	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.94e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.91e-05	0.000327	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	4.91e-05	0.000326	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—focal segmental glomerulosclerosis	4.9e-05	0.000326	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	4.71e-05	0.000313	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	4.68e-05	0.000311	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.65e-05	0.00031	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.63e-05	0.000308	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	4.54e-05	0.000302	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.52e-05	0.0003	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.5e-05	0.000299	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.49e-05	0.000299	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AGT—focal segmental glomerulosclerosis	4.46e-05	0.000297	CbGpPWpGaD
Dabrafenib—RAF1—Disease—LPL—focal segmental glomerulosclerosis	4.44e-05	0.000295	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.31e-05	0.000287	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.25e-05	0.000283	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SERPINE1—focal segmental glomerulosclerosis	4.22e-05	0.000281	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.13e-05	0.000275	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	3.91e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	3.88e-05	0.000258	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.86e-05	0.000257	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.84e-05	0.000256	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	3.81e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.78e-05	0.000251	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.55e-05	0.000236	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—LPL—focal segmental glomerulosclerosis	3.5e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—focal segmental glomerulosclerosis	3.47e-05	0.000231	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—focal segmental glomerulosclerosis	3.42e-05	0.000228	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	3.3e-05	0.000219	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	3.24e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.2e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.11e-05	0.000207	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGT—focal segmental glomerulosclerosis	2.99e-05	0.000199	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.96e-05	0.000197	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.95e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.94e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SERPINE1—focal segmental glomerulosclerosis	2.92e-05	0.000194	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	2.9e-05	0.000193	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.87e-05	0.000191	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	2.77e-05	0.000184	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.67e-05	0.000178	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—focal segmental glomerulosclerosis	2.66e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.66e-05	0.000177	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.53e-05	0.000168	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.46e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.46e-05	0.000163	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.33e-05	0.000155	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—focal segmental glomerulosclerosis	2.3e-05	0.000153	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.26e-05	0.000151	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	2.13e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.04e-05	0.000136	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	2.01e-05	0.000134	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.86e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—focal segmental glomerulosclerosis	1.84e-05	0.000123	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	1.77e-05	0.000118	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	1.75e-05	0.000117	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	1.72e-05	0.000114	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.57e-05	0.000104	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	1.56e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	1.5e-05	9.97e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.43e-05	9.55e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	1.32e-05	8.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.29e-05	8.58e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	1.15e-05	7.65e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	1.08e-05	7.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	9.24e-06	6.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	7.09e-06	4.72e-05	CbGpPWpGaD
